Harsh Singh, MD
Neurology · Tucson, AZNPI 1801888433
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $467 of the $532 with a category attached, or 87.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $202 and has fallen 85.9% since, to $28 in 2025. That places this record below the midpoint for neurology clinicians in AZ, where the typical reported total is $1,232.
Across 32 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$84
- Biogen$65
- Lilly USA, LLC$39
- Tanabe Pharma America, Inc.$38
- UCB, Inc.$37
- AbbVie$30
- plus $240 from 13 others
What the payments were for
- Food & beverage$46788%
- Education$6512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 4 | $84 |
| Biogen | 2 | $65 |
| Lilly USA, LLC | 3 | $39 |
| Tanabe Pharma America, Inc. | 3 | $38 |
| UCB, Inc. | 2 | $37 |
| AbbVie(2 entities) | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| EMD Serono, Inc. | 2 | $29 |
| SK Life Science, Inc. | 2 | $27 |
| Avid Radiopharmaceuticals, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Neurelis, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Sanofi | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Amgen | 1 | $11 |
| MDD US Operations, LLC | 1 | $11 |
How this compares
$532 in reported general payments places this provider in the 35th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 12 | $12,383 |
| Carbamazepine ErCarbamazepine | 17 | $1,518 |
| Levetiracetam | 28 | $1,289 |
| Topiramate | 45 | $1,166 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 26 | $772 |
| Gabapentin | 53 | $714 |
| Primidone | 34 | $708 |
| Hydroxychloroquine Sulfate | 16 | $451 |
| Tramadol Hcl | 17 | $395 |
| RizatriptanRizatriptan Benzoate | 15 | $356 |
| Lamotrigine | 13 | $264 |
| Diclofenac Sodium | 11 | $206 |
| Donepezil Hcl | 25 | $186 |
| Cyclobenzaprine Hcl | 12 | $185 |
| Duloxetine Hcl | 14 | $183 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tucson
- Francisco ValdiviaTucson$137K
- Cynthia ReedTucson$111K
- Yeeck SimTucson$38K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.